Patents Assigned to Camurus AB
-
Patent number: 12161640Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: November 2, 2023Date of Patent: December 10, 2024Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Patent number: 11135215Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: January 6, 2021Date of Patent: October 5, 2021Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Patent number: 11110084Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: January 6, 2021Date of Patent: September 7, 2021Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Patent number: 10912772Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: May 22, 2020Date of Patent: February 9, 2021Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Publication number: 20180256496Abstract: The present invention relates to an injectable pre-formulation comprising a low viscosity mixture of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one oxygen containing organic solvent; d) at least one 5HT3 antagonist; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. Such compositions may additionally comprise polar solvents and/or further active agents such as opioid agonists and/or antagonists. Methods of treatment, particularly for management of nausea and vomiting such as for post-operative nausea and vomiting and/or therapy induced nausea and vomiting are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.Type: ApplicationFiled: September 16, 2016Publication date: September 13, 2018Applicants: Camurus AB, Camurus ABInventors: Fredrik Tiberg, Markus Johnsson, Justas Barauskas
-
Patent number: 9937164Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.Type: GrantFiled: July 26, 2013Date of Patent: April 10, 2018Assignee: Camurus ABInventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
-
Patent number: 8920782Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: December 9, 2005Date of Patent: December 30, 2014Assignee: Camurus ABInventors: Fredrik Joabsson, Margareta Linden, Krister Thuresson, Fredrik Tiberg
-
Patent number: 8871712Abstract: Pre-formulations of a low viscosity mixture containing: a) at least one diacyl glycerol; b) at least one phosphatidyl choline; c) at least one oxygen containing organic solvent; d) at least one somatostatin analog are described. The pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The pre-formulations are useful for generating depot composition far the controlled release of somatostatin analogs such as octreotide. Methods of treatment comprising the administration of such formulations are also provided, as are pre-filled administration devices and kits containing the formulations.Type: GrantFiled: December 9, 2005Date of Patent: October 28, 2014Assignee: Camurus ABInventors: Fredrik Joabsson, Markus Johnsson, Andreas Norlin, Fredrik Tiberg
-
Patent number: 8865021Abstract: The present invention relates to compositions containing at least one cationic peptide active agent, at least one neutral structure forming amphiphile, at least one anionic structure forming amphiphile and optionally at least one solvent wherein the composition is in the form of a non-lamellar phase structure and/or forms a nonlamellar phase structure on exposure to body fluids. The invention also relates to methods for protecting peptides from enzymic degredation in vivo and to compositions in which the peptide active agent is so protected.Type: GrantFiled: November 5, 2004Date of Patent: October 21, 2014Assignee: Camurus ABInventors: Fredrik Joabsson, Fredrik Tiberg
-
Patent number: 8546326Abstract: The present invention relates to compositions forming a low viscosity mixture of: a) at least one neutral diacyl lipid, such as a diacyl glycerol; b) at least one phospholipid, such as a phosphatidyl choline; c) at least one biotolerable solvent, such as an oxygen containing solvent; d) at least one GLP-1 analogue; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, especially in treating diabetes, and to pre-filled administration devices and kits containing the formulations.Type: GrantFiled: June 6, 2006Date of Patent: October 1, 2013Assignee: Camurus ABInventors: Fredrik Joabsson, Markus Johnsson, Fredrik Tiberg
-
Patent number: 8541400Abstract: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid. The invention additionally provides a method for forming non-lamellar particles from such compositions, and pharmaceutical formulations containing the compositions, plus non-lamellar particles formable from the compositions.Type: GrantFiled: August 4, 2005Date of Patent: September 24, 2013Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Joabsson, Fredrik Tiberg
-
Publication number: 20120269772Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: Camurus ABInventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Patent number: 8236292Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: June 6, 2005Date of Patent: August 7, 2012Assignee: Camurus ABInventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Patent number: 8236755Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one opioid bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: May 14, 2007Date of Patent: August 7, 2012Assignee: Camurus ABInventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Patent number: 8187629Abstract: The present invention relates to particulate compositions comprising at least 50% of dioleoyl phosphatidyl ethanolamine (DOPE) and 1 to 50% of Polysorbate 80 (P80). All parts are by weight relative to the sum of the weights of a+b and the compositions comprise non-lamellar particles or form non-lamellar particles when contacted with an aqueous fluid. The compositions have advantageous stability and low toxicity and the invention also relates to pharmaceutical compositions thereof.Type: GrantFiled: January 21, 2005Date of Patent: May 29, 2012Assignee: Camurus ABInventors: Justas Barauskas, Fredrik Tiberg
-
Patent number: 8182834Abstract: The present invention provides a particulate composition including; a) at least 50% of at least one structure forming amphiphile, b) 0 to 40% of at least one structure swelling amphiphile, and c) 2 to 20% of at least one dispersion stabilizing polymeric amphiphile, where all parts are by weight relative to the sum of the weights of a+b+c and wherein the composition comprises non-lamellar particles or forms non-lamellar particles when contacted with an aqueous fluid. Where component b) is 0% then component a) comprises at least two structure forming amphiphiles. The invention also provides pharmaceutical compositions of the compositions and kits containing the compositions for establishing a pharmaceutical formulation of an active agent.Type: GrantFiled: January 21, 2005Date of Patent: May 22, 2012Assignee: Camurus ABInventors: Markus Johnsson, Predrik Tiberg
-
Patent number: 8097239Abstract: The present invention relates to formulations of a lipid based controlled-release matrix, a polyhydroxy component and a bioactive agent. Such formulation are useful in the delivery of the bioactive compounds. The invention also relates to the use of a polyhydroxy component for increasing the solubility of a bioactive compound, especially a peptide in a lipid-based controlled-release matrix.Type: GrantFiled: October 24, 2007Date of Patent: January 17, 2012Assignee: Camurus ABInventors: Markus Johnsson, Fredrik Tiberg, Catalin Nistor
-
Patent number: 5260282Abstract: A saliva substitute, the characteristic feature of which is that it comprises water-soluble linseed polysaccharides. Said substitute is preferably in the form of an aqueous solution having a viscosity within the range of 1-30 mPa.s, most preferably 2-10 mPa.s. The substitute can be prepared by extracting the polysaccharides from linseed by means of water or a water solution containing inorganic salts. In addition to the fact that said substitute is useful as a saliva substitute it can also be utilized as a carrier for pharmaceuticals adapted for oral applications.Type: GrantFiled: April 6, 1992Date of Patent: November 9, 1993Assignee: Camurus ABInventors: Rolf Attstrom, Per O. Glantz, Hakan Hakansson, Kare Larsson
-
Patent number: 5001062Abstract: An article adapted for applications where there is contact with blood and especially in medical applications is prepared by adsorbing the enzyme, lysozyme or derivative thereof, onto a substrate and then adsorbing heparin or a heparin-based material to the enzyme. The substrate is preferably a metal or polymeric material.Type: GrantFiled: November 14, 1988Date of Patent: March 19, 1991Assignee: Camurus ABInventors: Kare V. Larsson, Sven E. Bergentz, Bengt L. T. Lindblad